Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide
Source: ClinicalTrials.gov NCT01219738 ↗Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Airway Blood Flow (Qaw) |
22.3; 29.4; 34.1; 28.2; 5.1 | — |
| SECONDARY Forced Expiratory Volume in 1 Second (FEV1) |
0.1; 3.2; 1.6; 3.2; 0.8 | — |
Eligibility Criteria
Inclusion Criteria
Twenty lifetime nonsmokers moderate or severe asthmatics; FEV1≥50 of predicted on the screening day
Exclusion Criteria
Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women; Cardiovascular disease and/or use of cardiovascular medication; Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance; Acute respiratory infection and or acute exacerbation of asthma within four weeks prior to the study; Use of systemic glucocorticosteroids within 4 weeks prior to the study; Daily ICS dose (fluticasone or budesonide) > 500ug; Diabetes mellitus
Data sourced from ClinicalTrials.gov (NCT01219738). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.